CCCR [China Commercial Credit] SC 13G:
[]
AMC [AMC ENTERTAINMENT] 8-K: (Original Filing)
[INVESTOR RELATIONS: John Merriwether, 866-248-3872 InvestorRelations@amctheatres.com MEDIA CONTACTS: Ryan Noonan, (913) 213-2183 rnoonan@amctheatres.com AMC ENTERTAINMENT INC. ANNOUNCES SENIOR SUBORDINATED NOTES OFFERING Leawood, Kansas The Company intends to use the net proceeds from this private offering to pay the consideration for the tender offer to purchase all of the Companys outstanding $600.0 million aggregate principal amount of 9.75% Senior Subordinated Notes] [Summary Historical Financial and Operating Data The following summary historical financial and operating data set forth our historical financial and operating data for (i) the twelve months ended March 31, 2015, (ii) the three months ended March 31, 2015, (iii) the three months ended March 31, 2014, (iv) the twelve months ended December 31, 2014, (v) the twelve months ended] [Item 7.01 Regulation FD Disclosure]
AMC [AMC ENTERTAINMENT] 8-K: INVESTOR RELATIONS: John Merriwether, 866-248-3872 InvestorRelations@amctheatres.com MEDIA CONTACTS:
[INVESTOR RELATIONS: John Merriwether, 866-248-3872 InvestorRelations@amctheatres.com MEDIA CONTACTS: Ryan Noonan, (913) 213-2183 rnoonan@amctheatres.com AMC ENTERTAINMENT INC. ANNOUNCES SENIOR SUBORDINATED NOTES OFFERING Leawood, Kansas The Company intends to use the net proceeds from this private offering to pay the consideration for the tender offer to purchase all of the Companys outstanding $600.0 million aggregate principal amount of 9.75% Senior Subordinated Notes] [Summary Historical Financial and Operating Data The following summary historical financial and operating data set forth our historical financial and operating data for (i) the twelve months ended March 31, 2015, (ii) the three months ended March 31, 2015, (iii) the three months ended March 31, 2014, (iv) the twelve months ended December 31, 2014, (v) the twelve months ended] [Item 7.01 Regulation FD Disclosure]
CO [China Cord Blood] 6-K: (Original Filing)
[China Cord Blood Corporations Special Committee Appoints As previously announced, the Companys board of directors formed the Special Committee to review and evaluate the April 27, 2015 non-binding proposal from Golden Meditech Holdings Limited (Golden Meditech) to acquire all of the outstanding ordinary shares of the Company not already directly or indirectly owned by Golden Meditech in a going private] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description]
CAAS [CHINA AUTOMOTIVE SYSTEMS] EFFECT: (Original Filing)
[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]
CO [China Cord Blood] 6-K: China Cord Blood Corporations Special Committee Appoints As
[China Cord Blood Corporations Special Committee Appoints As previously announced, the Companys board of directors formed the Special Committee to review and evaluate the April 27, 2015 non-binding proposal from Golden Meditech Holdings Limited (Golden Meditech) to acquire all of the outstanding ordinary shares of the Company not already directly or indirectly owned by Golden Meditech in a going private] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description]
CAAS [CHINA AUTOMOTIVE SYSTEMS] EFFECT: .FormData {color: blue; background-color: white; font-size: small; font-family:
[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13D/A: (Original Filing)
[13D CUSIP No. 830884102 Page 2 1. Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above Persons John M. Gregory 2. Check the Appropriate Box if a Member of a Group (See Instructions) ¨ x (a) 3. SEC Use Only 4. Source of Funds (See Instructions) OO 5. 6.]
